



Supplemental Data


Supplemental Figures




Supplemental Figure 1. Pharmacokinetic and pharmacodynamic analysis of the novel mobilization regimen. (A) DBA2/J mice received an injection of CWHM-823+tGro-β (3 mg/kg CWHM823 + 2.5 mg/kg tGro-β) either subcutaneously (s.c.), intraperitoneally (i.p.) or intravenously (i.v.). Numbers of circulating CFU-C at the indicated timepoints after the injection are shown. Data represent mean \pm SEM, $n=4-6$. (B) DBA2/J mice received an injection of CWHM-823 alone (3 mg/kg) or the combination CWHM-823+tGro-β (3 mg/kg CWHM823 + 2.5 mg/kg tGro-β) either subcutaneously (s.c.), intraperitoneally (i.p.) or intravenously (i.v.). Plasma concentrations of CWHM-823 were determined by LC/MS. Data represent mean \pm SEM, $n=3$. (C) Time and dose-response kinetics of mobilization were analyzed in DBA2/J mice. Circulating CFU-C were enumerated up to 8 hrs following an injection of CWHM-823 alone (3.0, 7.5 or 15 mg/kg s.c.) or in combination with tGro-β (2.5 mg/kg, s.c.). Data represent mean \pm SEM, $n=5$. *** $p<0.001$, ** $p<0.01$. Statistical comparisons were made using linear mixed models, followed by step-down Bonferroni adjustment for multiple comparisons.




Supplemental Figure 2: Retention of CFU-C mobilization in model of poor mobilization. Two to three weeks after streptozotocin (200 mg/kg) or control buffer injection BALB/cJ mice were mobilized with either G-CSF (100 µg/kg, i.p, 9 doses, q12h) or the combination CWHM-823+tGro-β (3 mg/kg CWHM823 + 2.5 mg/kg tGro-β, timepoint 30 min after s.c injection). PB CFU-C were enumerated. Data represent mean±SEM, n=3-4. ***p<0.001. Statistical comparisons were made using ANOVA, followed by step-down Bonferroni adjustment for multiple comparisons.



Supplemental Figure 3. Cell cycle analysis of LSK cells. BALB/cJ mice were mobilized with G-CSF (100 µg/kg, i.p., 4 or 9 doses (2 or 5 days), q12h), tGro-β (2.5 mg/kg, s.c., timepoint 15 min), CWHM-823 (3.0 mg/kg, s.c., timepoint 60 min), AMD3100 (5.0 mg/kg, s.c., timepoint 60 min) or the combinations CWHM-823+tGro-β or AMD3100+tGro-β (doses same as for separate treatments, timepoint 30 min). Distribution of mobilized LSK in in G₀/G₁/G₂SM phases of the cell cycle was quantified based on Ki67 and 7-AAD staining. BM LSK were analyzed for comparison. Data represent mean±SEM, n=5.



Supplemental Figure 4. CXCR2 expression analysis. Expression of CXCR2 was assessed in mature and immature hematopoietic populations in the BM of wildtype BALB/c mice. **(A)** Gating strategy and markers used to distinguish different cell populations. **(B)** CXCR2 gene expression in sorted populations was quantified using real-time PCR. Data represent mean \pm SEM, n=3-9. **C**, CXCR2 surface expression was assessed by flow cytometry. Data represent mean \pm SEM, n=4.



Supplemental Figure 5. Role of proteases on mobilization. (A-C) Mobilization in MMP9 knockout mice. MMP9 knockout and corresponding control mice (FVB background in **A** and B6 background in **B**) were mobilized with tGro- β (2.5 mg/kg, s.c., timepoint 15 min), CWHM-823 (3.0 mg/kg, s.c., timepoint 60 min), AMD3100 (5.0 mg/kg, s.c., timepoint 60 min) or the combinations CWHM-823+tGro- β and AMD3100+tGro- β (doses same as for separate treatments, timepoint 30 min). Numbers of circulating CFU-C were assessed and compared to baseline level. Each bar represents the mean \pm SEM, n=34-36 for baseline, n=5-6 for mobilized mice. (C) Wildtype BALB/cJ mice received two injections of the broad-spectrum inhibitor of matrix metalloproteases Batimastat (12 and 2 hrs prior to mobilization, 25 mg/kg i.p.). Control mice were pretreated with DMSO/oil solution. Mice were treated as in D/E and numbers of circulating progenitors (CFU-C) compared to baseline levels. Each bar represents the mean \pm SEM, n=10. ***p<0.001, **p<0.01. Statistical comparisons were made using ANOVA, followed by step-down Bonferroni adjustment for multiple comparisons.

Supplemental Tables

Supplemental Table 1: Properties of VLA4 integrin antagonists tested in the study.

VLA4 antagonist	Binding Affinity (IC ₅₀ ; nM)					Aqueous solubility (pH7)	
	$\alpha 4\beta 1$	$\alpha 4\beta 7$	$\alpha V\beta 3$	$\alpha 5\beta 1$	$\alpha 2\beta 1$	$\mu\text{g/mL}$	clogP
BIO5192	6.5	>1000	>1000	>1000	>1000	0.08	5.4
Firategrast	3.2	5.8	>1000	>1000	>1000	2.67	3.1
CWHM-842	1.9	>1000	>1000	>1000	>1000	0.09	5.4
CWHM-822	4.3	22.1	N.D.	N.D.	N.D.	5.56	4.1
CWHM-823	2.0	1.5	>1000	>1000	82.7	4.45	3.1
CWHM-824	2.7	31.8	N.D.	N.D.	N.D.	0.57	5.7
CWHM-825	3.0	37.0	N.D.	N.D.	N.D.	0.15	3.2

Supplemental Table 2: Profiling of tGro-β for its agonistic activity against the gpcrMAX Panel.

GPCR ID	Assay Mode	Conc (μM)	Mean RLU	% Activity	GPCR ID	Assay Mode	Conc (μM)	Mean RLU	% Activity
ADCYAP1R1	Agonist	0.1	419720	-1%	GLP2R	Agonist	0.1	127540	1%
ADORA3	Agonist	0.1	174160	2%	GPR1	Agonist	0.1	146020	1%
ADRA1B	Agonist	0.1	418180	2%	GPR103	Agonist	0.1	66080	4%
ADRA2A	Agonist	0.1	246540	3%	GPR109A	Agonist	0.1	1058400	18%
ADRA2B	Agonist	0.1	309400	1%	GPR109B	Agonist	0.1	267680	0%
ADRA2C	Agonist	0.1	146720	1%	GPR119	Agonist	0.1	347900	7%
ADRB1	Agonist	0.1	177800	2%	GPR120	Agonist	0.1	48020	1%
ADRB2	Agonist	0.1	22400	1%	GPR35	Agonist	0.1	397600	2%
AGTR1	Agonist	0.1	293720	2%	GPR92	Agonist	0.1	160300	0%
AGTRL1	Agonist	0.1	351120	2%	GRPR	Agonist	0.1	27300	1%
AVPR1A	Agonist	0.1	19040	0%	HCRTR1	Agonist	0.1	146580	0%
AVPR1B	Agonist	0.1	29540	0%	HCRTR2	Agonist	0.1	113120	0%
AVPR2	Agonist	0.1	710780	2%	HRH1	Agonist	0.1	919240	-1%
BDKRB1	Agonist	0.1	21560	1%	HRH2	Agonist	0.1	122640	1%
BDKRB2	Agonist	0.1	548940	0%	HRH3	Agonist	0.1	113680	7%
BRS3	Agonist	0.1	160160	3%	HRH4	Agonist	0.1	791980	-5%
C3AR1	Agonist	0.1	60760	1%	HTR1A	Agonist	0.1	996940	0%
C5AR1	Agonist	0.1	129500	1%	HTR1B	Agonist	0.1	1654660	2%
C5L2	Agonist	0.1	548100	4%	HTR1E	Agonist	0.1	31920	1%
CALCR	Agonist	0.1	103600	2%	HTR1F	Agonist	0.1	502460	-4%
CALCRL-RAMP1	Agonist	0.1	86100	1%	HTR2A	Agonist	0.1	721560	1%
CALCRL-RAMP2	Agonist	0.1	92540	0%	HTR2C	Agonist	0.1	1497720	-3%
CALCRL-RAMP3	Agonist	0.1	285180	1%	HTR5A	Agonist	0.1	1080660	2%
CALCR-RAMP2	Agonist	0.1	112700	1%	KISS1R	Agonist	0.1	36680	1%
CALCR-RAMP3	Agonist	0.1	7840	0%	LHCGR	Agonist	0.1	29680	-1%
CCKAR	Agonist	0.1	58380	1%	LTBR4	Agonist	0.1	226100	1%
CCKBR	Agonist	0.1	643580	3%	MC1R	Agonist	0.1	14000	-1%
CCR10	Agonist	0.1	129360	1%	MC3R	Agonist	0.1	9100	0%
CCR1	Agonist	0.1	1506260	9%	MC4R	Agonist	0.1	25060	2%
CCR2	Agonist	0.1	145180	2%	MC5R	Agonist	0.1	38080	1%
CCR3	Agonist	0.1	203980	6%	MCHR1	Agonist	0.1	44800	2%
CCR4	Agonist	0.1	207200	1%	MCHR2	Agonist	0.1	61740	1%
CCR5	Agonist	0.1	132720	0%	MLNR	Agonist	0.1	133420	1%
CCR6	Agonist	0.1	147280	1%	MRGPRX1	Agonist	0.1	552300	1%
CCR7	Agonist	0.1	866460	1%	MRGPRX2	Agonist	0.1	212940	1%
CCR8	Agonist	0.1	48580	1%	MTNR1A	Agonist	0.1	94920	3%
CCR9	Agonist	0.1	175700	1%	NMBR	Agonist	0.1	35420	0%
CHRM1	Agonist	0.1	860860	3%	NMU1R	Agonist	0.1	90440	0%
CHRM2	Agonist	0.1	39760	0%	NPBWR1	Agonist	0.1	44800	-5%
CHRM3	Agonist	0.1	73920	1%	NPBWR2	Agonist	0.1	166460	0%
CHRM4	Agonist	0.1	334040	-1%	NPPFR1	Agonist	0.1	58800	3%
CHRM5	Agonist	0.1	1893360	4%	NPSR1B	Agonist	0.1	26180	0%
CMKLR1	Agonist	0.1	77980	0%	NPY1R	Agonist	0.1	33320	0%
CNR1	Agonist	0.1	37520	1%	NPY2R	Agonist	0.1	132300	0%
CNR2	Agonist	0.1	199360	1%	NTSR1	Agonist	0.1	265160	2%
CRHR1	Agonist	0.1	349020	0%	OPRD1	Agonist	0.1	59640	-1%
CRHR2	Agonist	0.1	100100	0%	OPRK1	Agonist	0.1	41860	0%
CRTH2	Agonist	0.1	314160	1%	OPRL1	Agonist	0.1	123620	1%
CX3CR1	Agonist	0.1	10360	1%	OPRM1	Agonist	0.1	73360	0%
CXCR1	Agonist	0.1	434700	7%	OXER1	Agonist	0.1	65660	1%
CXCR2	Agonist	0.1	972720	137%	OXTR	Agonist	0.1	30800	0%
CXCR3	Agonist	0.1	556500	4%	P2RY1	Agonist	0.1	346640	-3%
CXCR4	Agonist	0.1	101640	11%	P2RY11	Agonist	0.1	41020	1%
CXCR5	Agonist	0.1	261380	2%	P2RY12	Agonist	0.1	115920	0%
CXCR6	Agonist	0.1	21140	-1%	P2RY2	Agonist	0.1	345940	-12%
CXCR7	Agonist	0.1	144340	1%	P2RY4	Agonist	0.1	476280	3%
DRD1	Agonist	0.1	100800	1%	P2RY6	Agonist	0.1	243880	1%
DRD2L	Agonist	0.1	77140	2%	PPYR1	Agonist	0.1	19320	3%
DRD2S	Agonist	0.1	208880	0%	PRLHR	Agonist	0.1	41720	4%
DRD3	Agonist	0.1	481600	8%	PROKR1	Agonist	0.1	52780	0%
DRD4	Agonist	0.1	22820	1%	PROKR2	Agonist	0.1	13860	0%
DRD5	Agonist	0.1	11480	0%	PTAFR	Agonist	0.1	1035720	2%
EBI2	Agonist	0.1	60620	-1%	PTGER2	Agonist	0.1	9800	4%
EDG1	Agonist	0.1	105560	-1%	PTGER3	Agonist	0.1	649880	4%
EDG3	Agonist	0.1	972440	1%	PTGER4	Agonist	0.1	99540	1%
EDG4	Agonist	0.1	192360	5%	PTGFR	Agonist	0.1	7980	0%
EDG5	Agonist	0.1	201460	0%	PTGIR	Agonist	0.1	279580	2%
EDG6	Agonist	0.1	215600	-4%	PTHR1	Agonist	0.1	185640	0%
EDG7	Agonist	0.1	125440	2%	PTHR2	Agonist	0.1	143640	0%
EDNRA	Agonist	0.1	22540	0%	RXFP3	Agonist	0.1	84280	5%
EDNRB	Agonist	0.1	140980	1%	SCTR	Agonist	0.1	260120	1%
F2R	Agonist	0.1	102340	0%	SSTR1	Agonist	0.1	15400	2%
F2RL1	Agonist	0.1	596540	3%	SSTR2	Agonist	0.1	5180	0%
F2RL3	Agonist	0.1	1121260	3%	SSTR3	Agonist	0.1	200620	2%
FFAR1	Agonist	0.1	373940	1%	SSTR5	Agonist	0.1	268940	3%
FPR1	Agonist	0.1	1194760	4%	TACR1	Agonist	0.1	847280	1%
FPRL1	Agonist	0.1	133840	0%	TACR2	Agonist	0.1	399560	1%
FSHR	Agonist	0.1	169120	1%	TACR3	Agonist	0.1	119980	0%
GALR1	Agonist	0.1	656320	1%	TBXA2R	Agonist	0.1	122920	0%
GALR2	Agonist	0.1	250600	1%	TRHR	Agonist	0.1	15820	0%
GCGR	Agonist	0.1	195020	0%	TSHR(L)	Agonist	0.1	7000	-1%
GHSR	Agonist	0.1	339920	0%	UTR2	Agonist	0.1	27720	-1%
GIPR	Agonist	0.1	16380	0%	VIPR1	Agonist	0.1	318640	1%
GLP1R	Agonist	0.1	260680	0%	VIPR2	Agonist	0.1	219940	0%

Supplemental Table 3: List of genes differentially regulated in CWHM-823+tGro- β mobilized compared to BM LSK.

GeneName	p-value	Fold-Change
Lilrb4	1.85E-01	9.31E+02
Nr4a3	1.55E-04	9.15E+02
Socs3	5.04E+00	8.23E+02
Ahnak	3.06E+00	7.71E+02
Nfkbid	2.96E-01	7.42E+02
Fosb	2.79E-01	7.40E+02
Adgre5	1.67E+00	7.36E+02
Dusp18	5.66E+00	6.71E+02
S100a10	1.69E+00	6.12E+02
Hbb-bt	5.14E-01	6.01E+02
TC1775906	8.44E-01	5.93E+02
Dyrk3	3.48E-02	5.18E+02
Pde4b	9.44E-01	5.12E+02
Emp1	6.98E-01	5.11E+02
Egr2	3.85E+00	5.07E+02
Vpreb3	6.85E+00	4.34E+02
Slc2a3	5.85E+00	4.31E+02
Marcksl1	3.01E+00	4.07E+02
Stk17b	5.12E-01	4.04E+02
Rnf19b	4.31E-01	3.98E+02
A_55_P2159595	4.78E-01	3.43E+02
Tshb	2.03E+00	3.04E+02
Atf3	1.20E+00	3.01E+02
Hba-a2	8.42E-02	2.93E+02
Spry1	5.11E-03	2.83E+02
Nr4a1	7.19E-01	2.82E+02
Trib1	1.83E-02	2.54E+02
Pmaip1	5.08E+00	2.47E+02
Plk3	3.21E+00	2.25E+02
Csrnp1	3.25E-02	2.24E+02
Klf2	2.31E+00	2.22E+02
Hba-a1	5.03E-02	2.16E+02
Cd69	7.41E-01	2.03E+02
Sgk1	1.14E+00	1.82E+02
Rasgef1b	8.41E-02	1.58E+02
Lmna	4.77E-01	1.44E+02
Klf4	1.36E+00	1.10E+02
Nr4a2	5.89E-01	1.05E+02
Gzmb	3.02E+00	1.02E+02
Egr3	1.66E-02	8.56E+01
Tnfsf11	4.59E-02	7.99E+01
Klf6	6.21E-01	7.36E+01
Gpr171	2.08E+00	4.66E+01
LOC105247474	4.29E+00	-3.56E+02
Rxfp1	6.87E+00	-5.40E+02

Supplemental Table 4: List of genes differentially regulated in CWHM-823+tGro- β compared to G-CSF mobilized LSK.

GeneName	p-value	Fold-Change
Vpreb3	4.23E-01	8.54E+02
Tnfsf11	5.40E-02	7.66E+02
Pou2af1	5.85E+00	7.02E+02
ENSMUST00000103410 (Igkc)	2.12E+00	6.31E+02
Spry1	1.49E+00	4.93E+02
Thbs1	8.36E+00	4.22E+02
Ccr9	3.57E+00	3.69E+02
Cd79a	3.55E+00	2.33E+02
A_55_P2180521	5.12E-01	2.22E+02
Nr4a3	4.70E-04	1.88E+02
Bpifb5	4.13E-01	1.19E+02
Galnt6	3.94E+00	-2.99E+01
Cav2	2.02E-02	-8.51E+01
Pira11	1.36E-01	-1.08E+02
Dll1	4.04E-02	-1.28E+02
Tgfb1	1.32E-01	-1.46E+02
Selp	1.20E-01	-1.46E+02
Col18a1	8.01E-03	-1.47E+02
Pirb	6.81E-01	-1.47E+02
Pira7	6.70E-01	-1.93E+02
TC1682680	4.99E+00	-2.18E+02
1110008P14Rik	1.24E+00	-3.22E+02
3830612M24	3.38E+00	-3.24E+02
Rps6ka3	8.50E+00	-3.25E+02
Plscr1	6.31E+00	-3.41E+02
Dpysl3	6.88E+00	-3.47E+02
Anxa1	4.71E+00	-3.48E+02
Il4ra	8.81E+00	-3.62E+02
Fads3	2.23E+00	-3.64E+02
Prtn3	2.20E+00	-3.84E+02
Hpse	7.51E-01	-3.99E+02
Gda	2.69E-01	-4.22E+02
Tgm1	3.88E+00	-4.35E+02
Gas2l1	2.67E+00	-4.48E+02
Vldlr	1.03E+00	-4.57E+02
Nhs12	7.28E+00	-4.58E+02
Ms4a3	5.37E+00	-4.60E+02
Pira6	2.69E+00	-4.62E+02
Endod1	7.66E+00	-4.96E+02
Lilra6	7.41E+00	-5.87E+02
Lag3	1.15E-01	-5.99E+02
Ecm1	8.41E-01	-6.12E+02
Csf2rb	3.30E-01	-6.59E+02
Lilrb4	4.22E-01	-7.40E+02
Anxa2	2.86E+00	-7.42E+02
Pmaip1	9.79E-03	-7.85E+02
Id1	4.56E+00	-8.28E+02
S100a4	1.89E-01	-8.40E+02
Csf2rb2	8.24E-01	-8.57E+02
S100a6	2.89E+00	-8.84E+02
Bcl3	6.44E-01	-9.15E+02
Mrgpra2b	6.87E+00	-9.30E+02
Grhl1	3.30E+00	-9.75E+02

Supplemental Table 5: List of genes differentially regulated in CWHM-823+tGro- β compared to AMD3100 mobilized LSK.

GeneName	p-value	Fold-Change	GeneName	p-value	Fold-Change
Insm1	6.74E-04	9.00E+05	Ldhb	3.31E-04	3.84E+05
Tspan8	1.76E-04	8.84E+05	Ttc21b	4.10E-04	3.83E+05
ENSMUST00000058162	5.98E-04	8.04E+05	Mdm1	4.51E-04	3.83E+05
Usp45	1.17E-03	7.76E+05	Slc12a2	6.24E-04	3.80E+05
Rps6ka5	4.13E-04	7.76E+05	Sdha	3.93E-04	3.78E+05
ENSMUST00000103311	7.28E-04	7.46E+05	ENSMUST00000176764	2.41E-04	3.78E+05
2310026L22Rik	2.90E-04	7.15E+05	Ppan	3.52E-04	3.75E+05
ENSMUST00000103486	1.46E-03	7.05E+05	ENSMUST00000025904	1.72E-04	3.75E+05
Dcaf12l1	7.73E-04	6.89E+05	Inpp1	2.05E-04	3.69E+05
Gphn	1.13E-03	6.86E+05	1810011H11Rik	6.90E-04	3.66E+05
Tmem29	1.18E-03	6.59E+05	Jpx	7.12E-04	3.64E+05
Klf9	1.48E-03	6.57E+05	Ptpn21	6.69E-04	3.63E+05
Abcg2	1.04E-03	6.17E+05	Aldh7a1	2.06E-04	3.63E+05
Gnpda2	2.07E-04	6.10E+05	Dancr	9.45E-04	3.61E+05
Rap1gap	1.31E-03	5.98E+05	Klf8	4.70E-04	3.57E+05
Gm12592	4.42E-04	5.93E+05	Adprm	6.74E-04	3.55E+05
Dip2c	5.15E-04	5.90E+05	Ackr2	1.03E-03	3.55E+05
Kazn	3.34E-04	5.85E+05	Fhl1	1.14E-03	3.54E+05
Arl5c	1.38E-03	5.74E+05	Slamf1	1.01E-03	3.53E+05
Gimap5	1.37E-03	5.71E+05	ENSMUST00000135671	8.02E-04	3.53E+05
Xk	1.02E-03	5.48E+05	2410016O06Rik	2.60E-04	3.49E+05
Herpud2	7.05E-04	5.39E+05	Rasgef1b	2.82E-04	3.48E+05
Dars2	3.47E-04	5.31E+05	Mogs	2.79E-04	3.47E+05
0610009L18Rik	1.29E-03	5.31E+05	Slit2	5.12E-04	3.44E+05
Ndfip2	6.52E-04	5.30E+05	Ctsc	2.68E-04	3.43E+05
B630019K06Rik	1.48E-03	5.26E+05	Agpat6	5.91E-04	3.43E+05
Sgk1	6.65E-04	5.07E+05	Ctps	1.38E-03	3.42E+05
Sccpdh	8.77E-04	5.06E+05	Rnf103	1.46E-03	3.40E+05
Lincpint	8.92E-04	4.96E+05	Sacm1l	1.09E-03	3.38E+05
Alkbh8	3.96E-04	4.94E+05	Spint2	5.75E-04	3.36E+05
Lincpint	1.36E-03	4.94E+05	Dock5	4.51E-04	3.34E+05
Armc3	1.17E-03	4.73E+05	Tmem40	2.60E-04	3.33E+05
Armcx1	1.44E-03	4.61E+05	Hells	4.89E-04	3.33E+05
Dhx29	1.47E-03	4.48E+05	Ccna2	6.22E-04	3.28E+05
Nr4a2	1.61E-04	4.42E+05	Erlin1	1.62E-04	3.28E+05
Maged1	3.62E-04	4.40E+05	Cpq	1.50E-04	3.27E+05
Deaf1	3.73E-04	4.33E+05	Mthfd1l	9.03E-04	3.26E+05
Cstf3	1.08E-03	4.31E+05	Stx12	4.15E-04	3.24E+05
C530008M17Rik	1.14E-03	4.30E+05	Stat5b	6.88E-04	3.23E+05
A_55_P2086835	8.03E-04	4.30E+05	Emc7	7.09E-04	3.22E+05
Chchd6	5.70E-04	4.25E+05	Sde2	1.31E-04	3.21E+05
Wls	3.97E-04	4.22E+05	Pbx3	1.12E-04	3.19E+05
Nol7	3.38E-04	4.20E+05	Ccdc53	1.46E-03	3.19E+05
Nr1d2	2.64E-04	4.13E+05	Fam73a	2.02E-04	3.19E+05
Lancl1	1.17E-03	4.13E+05	Stard7	3.26E-04	3.18E+05
Usp19	1.36E-04	4.12E+05	Piga	4.96E-04	3.18E+05
Pex1	4.94E-04	4.07E+05	Golim4	1.24E-03	3.17E+05
Zfp800	1.26E-03	4.00E+05	Tfr2	1.23E-03	3.17E+05
2310022B05Rik	1.03E-03	3.86E+05	lqce	8.68E-04	3.16E+05
Afp	4.42E-04	3.86E+05	Urod	3.23E-04	3.16E+05
Adal	5.74E-04	3.86E+05	Rpn2	1.14E-03	3.16E+05
Rap1gap	2.09E-02	3.84E+05	Thbs1	3.97E-04	3.15E+05
Otud6b	4.92E-04	3.84E+05	Cyb5r1	9.33E-04	3.14E+05

GeneName	p-value	Fold-Change	GeneName	p-value	Fold-Change
Phldb1	1.33E-03	3.14E+05	Ranbp2	1.10E-03	2.89E+05
Rabac1	7.02E-04	3.13E+05	Inafm1	1.28E-03	2.89E+05
Scyl2	6.43E-04	3.12E+05	Nsmf	1.43E-04	2.89E+05
Lonp2	5.48E-04	3.12E+05	1700071A11Rik	1.28E-03	2.88E+05
Hacd4	3.99E-04	3.11E+05	Slc22a18	1.09E-03	2.88E+05
Gabarapl1	3.65E-04	3.10E+05	Igfbp7	1.39E-03	2.88E+05
Slc25a28	6.39E-04	3.09E+05	Comtd1	2.61E-04	2.87E+05
Pja1	4.30E-04	3.09E+05	Fam171a1	1.47E-03	2.87E+05
Laptm4b	7.48E-04	3.08E+05	Slc2a3	5.58E-04	2.86E+05
Cyp4v3	8.53E-04	3.06E+05	Tiparp	3.96E-04	2.86E+05
Pctp	1.33E-03	3.06E+05	Pi4ka	6.89E-04	2.86E+05
Dhx36	1.16E-03	3.06E+05	Cox4i1	1.21E-03	2.86E+05
Kras	9.18E-04	3.05E+05	Ell2	7.47E-04	2.85E+05
ENSMUST00000140653	8.12E-04	3.04E+05	Bgn	1.42E-03	2.85E+05
Emc6	9.68E-04	3.04E+05	Ptgs1	3.48E-04	2.85E+05
Sf3a3	3.54E-04	3.03E+05	Pds5b	6.02E-04	2.85E+05
Mansc1	3.63E-04	3.03E+05	Agtpbp1	9.82E-04	2.85E+05
Isca1	1.17E-04	3.03E+05	Eftud1	2.23E-04	2.85E+05
Hhex	1.43E-03	3.02E+05	Tmem164	6.55E-04	2.84E+05
Spidr	1.41E-04	3.01E+05	Nt5c3	1.17E-03	2.84E+05
Akr1e1	7.50E-04	3.01E+05	Pde8a	3.23E-04	2.83E+05
A830035O19Rik	9.74E-04	3.01E+05	Atr	1.04E-03	2.83E+05
Rnf187	3.20E-04	3.01E+05	Fech	5.25E-04	2.82E+05
Rab38	1.51E-04	3.00E+05	Pgm2	1.27E-03	2.82E+05
Arfgap2	1.24E-03	3.00E+05	Arhgap35	5.67E-04	2.82E+05
Il11ra1	2.68E-04	2.99E+05	Pja2	1.18E-03	2.81E+05
Stub1	3.01E-04	2.99E+05	Ipo11	1.11E-03	2.81E+05
Sil1	4.85E-04	2.98E+05	Snrpd1	4.08E-04	2.81E+05
Tmem9	1.20E-03	2.97E+05	Apool	5.53E-04	2.81E+05
Prdm16	4.38E-04	2.97E+05	Emid1	9.71E-04	2.80E+05
Slc35g1	9.69E-04	2.97E+05	Dpp3	9.58E-04	2.79E+05
Fkbp9	7.53E-04	2.97E+05	Krtcap3	5.20E-04	2.78E+05
Rnf113a2	1.49E-03	2.95E+05	Rbpms2	2.51E-04	2.77E+05
Cnbp	6.96E-04	2.95E+05	Trib1	8.39E-04	2.76E+05
NAP111930-1	5.82E-04	2.93E+05	Tbkbp1	5.75E-04	2.75E+05
Dtymk	9.12E-04	2.93E+05	Ufc1	5.78E-04	2.75E+05
Nus1	1.33E-03	2.93E+05	Homez	1.02E-04	2.75E+05
Ciapi1	4.00E-04	2.93E+05	Romo1	2.06E-04	2.74E+05
Kpnb1	7.38E-04	2.92E+05	Tlk2	1.08E-03	2.74E+05
Gbe1	5.96E-04	2.91E+05	Pqlc1	1.31E-03	2.74E+05
Cdk18	2.25E-04	2.91E+05	Mthfd1	4.67E-04	2.74E+05
Ralgapb	1.04E-03	2.91E+05	Pls3	3.16E-04	2.74E+05
Hmgcr	6.23E-04	2.91E+05	C1qbp	8.03E-04	2.74E+05
Tob2	2.54E-04	2.91E+05	Snrpb	5.56E-04	2.74E+05
Rnf11	8.97E-04	2.90E+05	Nudt9	2.66E-04	2.73E+05
Nubpl	1.08E-03	2.90E+05	Rab1b	1.37E-04	2.73E+05
Sgpp1	4.63E-04	2.90E+05	Psma3	6.88E-04	2.73E+05
Tex30	4.90E-04	2.90E+05	E130304I02Rik	5.65E-04	2.73E+05
Sec61a1	5.71E-04	2.90E+05	Phb	9.12E-04	2.71E+05
Mrps12	3.59E-04	2.90E+05	Derl1	1.16E-03	2.71E+05
Alg8	1.30E-03	2.89E+05	Syde1	9.61E-04	2.70E+05
Selenbp1	4.15E-04	2.89E+05	Glrx5	1.09E-03	2.70E+05
Dgkd	5.31E-04	2.89E+05	Eif4g1	5.60E-04	2.70E+05
Phldb1	1.33E-03	3.14E+05	Ranbp2	1.10E-03	2.89E+05
Rabac1	7.02E-04	3.13E+05	Inafm1	1.28E-03	2.89E+05

GeneName	p-value	Fold-Change	GeneName	p-value	Fold-Change
Tmem41a	4.54E-04	2.70E+05	Nufip2	9.04E-04	2.58E+05
Dnajb1	8.94E-04	2.70E+05	Psma1	1.27E-03	2.58E+05
Asns	1.01E-03	2.69E+05	Pus7	3.57E-04	2.58E+05
Hnrnpm	8.31E-04	2.69E+05	Edc4	1.32E-03	2.58E+05
Rfc1	1.45E-04	2.69E+05	Nfia	6.47E-04	2.58E+05
Mcoln2	9.08E-04	2.69E+05	Nup85	1.06E-03	2.58E+05
Smarca2	1.32E-03	2.68E+05	Uqcr11	7.55E-04	2.58E+05
Nap1l1	6.72E-04	2.68E+05	Sf3a1	1.45E-04	2.57E+05
BX514619	7.87E-03	2.68E+05	Nme2	2.60E-04	2.57E+05
Nhp2	5.74E-04	2.68E+05	ENSMUST00000000804	5.38E-04	2.57E+05
Rpl22	3.00E-04	2.68E+05	Psph	6.37E-04	2.57E+05
Hprt	2.47E-04	2.68E+05	Uqcrfs1	6.87E-04	2.57E+05
Bud31	5.29E-04	2.67E+05	Gtf2i	7.86E-04	2.57E+05
Adarb1	7.31E-04	2.67E+05	Minos1	1.29E-03	2.57E+05
Nop58	1.67E-04	2.66E+05	Prps1	2.74E-04	2.57E+05
Cyld	6.79E-04	2.66E+05	Ccdc50	1.33E-03	2.56E+05
Hspa14	9.10E-04	2.66E+05	Ncapd3	1.16E-03	2.56E+05
Socs2	1.98E-04	2.66E+05	Dhrs7b	8.13E-04	2.56E+05
Hgf	6.90E-04	2.66E+05	Usp2	1.64E-04	2.56E+05
Oxct1	6.61E-04	2.65E+05	Pold1	5.09E-04	2.55E+05
Uggt1	1.43E-03	2.65E+05	Gemin4	1.22E-03	2.55E+05
Tnfaip1	8.57E-04	2.65E+05	Mrpl52	9.37E-04	2.55E+05
G630025P09Rik	2.26E-04	2.64E+05	Atp5a1	6.03E-04	2.54E+05
Uqcrq	1.04E-03	2.64E+05	Fam110a	1.87E-04	2.54E+05
Tnfrsf10b	4.57E-04	2.64E+05	Exoc5	6.33E-04	2.54E+05
P2ry14	3.91E-04	2.64E+05	Ndufc2	1.30E-04	2.53E+05
Klhl15	3.70E-04	2.64E+05	Cdc37	1.02E-03	2.53E+05
Armxc2	1.32E-03	2.63E+05	Ppic	9.95E-04	2.53E+05
Minpp1	1.19E-03	2.63E+05	Cenpo	1.10E-03	2.53E+05
Tnks2	1.46E-03	2.63E+05	Ccdc132	5.29E-04	2.53E+05
Marcks1	4.05E-04	2.63E+05	Dnajc9	7.73E-04	2.53E+05
ENSMUST00000182143	9.69E-04	2.63E+05	Nsmaf	1.37E-03	2.52E+05
Impdh2	6.13E-04	2.63E+05	Sar1a	4.01E-04	2.52E+05
Ankrd39	1.51E-04	2.63E+05	Ttc33	4.66E-04	2.52E+05
Hnrnpdl	1.48E-03	2.63E+05	Aar2	1.27E-03	2.52E+05
Fancd2	1.46E-03	2.62E+05	Pcbd1	1.40E-04	2.51E+05
Gfpt1	1.29E-03	2.62E+05	Pdap1	4.80E-04	2.51E+05
Car2	1.11E-03	2.62E+05	Gng12	2.20E-04	2.51E+05
Rgs7bp	3.54E-04	2.62E+05	0610011F06Rik	1.22E-03	2.50E+05
Sgpl1	3.46E-04	2.61E+05	Ube2q1	4.47E-04	2.50E+05
A_55_P2073134	8.31E-04	2.61E+05	Ap1s3	3.40E-04	2.50E+05
Toporsos	9.04E-04	2.61E+05	Cpne1	1.29E-03	2.49E+05
Klhl22	5.43E-04	2.61E+05	Por	1.00E-03	2.49E+05
Ubl4	8.31E-04	2.61E+05	Psmb5	1.49E-03	2.49E+05
Pde4b	4.17E-04	2.60E+05	Scfd2	1.39E-03	2.49E+05
ENSMUST00000107485	8.06E-04	2.60E+05	Snx3	9.67E-04	2.49E+05
Irf3	1.48E-03	2.60E+05	Bnip3	8.22E-04	2.49E+05
Ash2l	1.49E-03	2.59E+05	A_55_P2156625	1.01E-03	2.49E+05
Fam174a	1.50E-03	2.59E+05	Mfn2	1.54E-04	2.49E+05
Trim13	5.31E-04	2.59E+05	Atp13a3	1.46E-03	2.48E+05
Hnrnpul2	2.92E-04	2.59E+05	Wdr77	5.08E-04	2.48E+05
Uba2	2.79E-04	2.59E+05	Mepce	1.03E-03	2.48E+05
Puf60	2.92E-04	2.58E+05	Ric8	8.44E-04	2.48E+05

GeneName	p-value	Fold-Change	GeneName	p-value	Fold-Change
Lrpprc	1.93E-04	2.48E+05	Mfng	5.94E-04	2.39E+05
Slc35b1	1.11E-03	2.48E+05	Ankrd27	7.97E-04	2.39E+05
Tmed8	1.26E-03	2.48E+05	Pcmt1	1.38E-03	2.39E+05
Mrps30	1.49E-03	2.48E+05	Whsc1	3.28E-04	2.39E+05
Rin3	1.32E-03	2.48E+05	Eif2ak4	1.42E-03	2.39E+05
Psm4	3.26E-04	2.48E+05	Rab1	2.51E-04	2.39E+05
Nfkbid	8.28E-04	2.47E+05	Epb4.1l4b	8.73E-04	2.39E+05
Zdhhc23	1.09E-03	2.47E+05	Ndufs1	1.02E-03	2.39E+05
Ube2e2	3.98E-04	2.47E+05	Phf10	3.06E-04	2.39E+05
Nenf	3.51E-04	2.47E+05	Akt1	9.67E-04	2.39E+05
Ubac1	1.49E-03	2.46E+05	Mtmr3	1.40E-03	2.39E+05
Magoh	9.87E-04	2.46E+05	Dnaja1	6.61E-04	2.38E+05
Fam96a	1.27E-04	2.46E+05	Cd28	1.42E-03	2.38E+05
Cnot2	5.32E-04	2.46E+05	Rab37	1.34E-03	2.38E+05
Anxa4	1.05E-03	2.46E+05	Fbxo11	1.85E-04	2.38E+05
Pigq	1.02E-03	2.46E+05	Tomm70a	1.27E-04	2.37E+05
ENSMUST00000185925	9.22E-04	2.46E+05	Pgpep1	9.28E-04	2.37E+05
Rrm1	1.08E-03	2.46E+05	Tmem230	1.22E-03	2.37E+05
D15Ert621e	3.21E-04	2.46E+05	Pigyl	1.03E-03	2.37E+05
ENSMUST00000036467	1.18E-03	2.45E+05	Sf3b4	5.62E-04	2.37E+05
2610002J02Rik	1.71E-04	2.45E+05	Pbdc1	1.45E-03	2.37E+05
Mrpl20	5.84E-04	2.45E+05	Fam60a	5.58E-04	2.37E+05
Polr2m	1.40E-03	2.45E+05	Skp1a	1.98E-04	2.36E+05
B4galt4	3.36E-04	2.45E+05	Rabep2	7.98E-04	2.36E+05
Polr2d	8.40E-04	2.45E+05	Nxn	6.29E-04	2.36E+05
Tmem176b	2.49E-04	2.44E+05	Psm3	3.80E-04	2.36E+05
Spns1	8.33E-04	2.44E+05	Naf1	5.44E-04	2.36E+05
Znrd1	8.69E-04	2.44E+05	Got1	1.15E-03	2.36E+05
Ica1	5.45E-04	2.44E+05	Rfwd3	1.90E-04	2.36E+05
Sqle	1.43E-04	2.44E+05	Cnih1	2.61E-04	2.36E+05
Gnl1	6.77E-04	2.43E+05	Ppp3cb	5.29E-04	2.36E+05
ENSMUST00000000153	1.41E-03	2.43E+05	Leo1	1.38E-03	2.36E+05
Wdr43	5.50E-04	2.43E+05	Sfr1	3.07E-04	2.35E+05
Mat2b	4.30E-04	2.42E+05	Wdr12	9.79E-04	2.35E+05
Slc23a2	6.07E-04	2.42E+05	Ppfibp1	9.29E-04	2.35E+05
Dpm3	9.58E-04	2.42E+05	Gpr171	1.16E-03	2.35E+05
Pcgf5	4.70E-04	2.42E+05	Tamm41	5.58E-04	2.35E+05
Arl6ip1	1.36E-03	2.42E+05	Macro1	1.06E-03	2.35E+05
Btg3	1.03E-03	2.41E+05	Pgrmc1	1.62E-04	2.35E+05
Mapk1	6.92E-04	2.41E+05	Smndc1	7.08E-04	2.34E+05
Spn	3.70E-04	2.41E+05	Acaa2	8.91E-04	2.34E+05
Fbxo7	8.95E-04	2.41E+05	Cd63	3.09E-04	2.34E+05
Atp6ap2	6.18E-04	2.41E+05	Nme4	3.28E-04	2.34E+05
Vdac3	3.22E-04	2.41E+05	A_55_P2043451	1.44E-03	2.34E+05
Rpn1	1.31E-04	2.41E+05	Leprot	1.24E-03	2.33E+05
Matr3	6.24E-04	2.41E+05	Cycs	2.33E-04	2.33E+05
1700123O20Rik	7.90E-04	2.40E+05	Alcam	1.13E-03	2.33E+05
Jade1	3.07E-04	2.40E+05	Wwp2	7.26E-04	2.33E+05
Creg1	9.51E-04	2.40E+05	Gabpb1	1.44E-03	2.32E+05
Nol6	5.22E-04	2.40E+05	Krtcap2	1.46E-03	2.32E+05
Lamp1	4.64E-04	2.40E+05	Khdrbs1	1.50E-04	2.32E+05
Atp2c1	3.51E-04	2.40E+05	Arhgef6	1.01E-03	2.32E+05
Hlf	1.17E-03	2.40E+05	Myl12a	9.29E-04	2.32E+05

GeneName	p-value	Fold-Change	GeneName	p-value	Fold-Change
Alg2	2.89E-04	2.32E+05	Foxp4	5.16E-04	2.23E+05
Plekha3	1.89E-04	2.31E+05	Tnfaip8	1.34E-03	2.23E+05
Zkscan17	9.33E-04	2.31E+05	Suc1a2	2.00E-04	2.22E+05
Timm8a1	3.59E-04	2.31E+05	ENSMUST00000049628	1.20E-03	2.22E+05
Ppp6r1	1.17E-03	2.31E+05	Ncoa6	4.71E-04	2.22E+05
Hbb-b2	6.45E-04	2.30E+05	A_55_P1999805	1.23E-03	2.22E+05
Pdcd6	1.59E-04	2.30E+05	Huwe1	7.89E-04	2.22E+05
M6pr	8.87E-04	2.30E+05	Gm5408	5.62E-04	2.21E+05
Pxylp1	5.20E-04	2.30E+05	Prkar1a	1.05E-03	2.21E+05
Sptssa	2.96E-04	2.30E+05	Pfkm	1.30E-03	2.21E+05
Ywhag	3.45E-04	2.30E+05	Cyfp2	4.54E-04	2.21E+05
A_55_P2049071	8.98E-04	2.30E+05	1810037117Rik	4.85E-04	2.21E+05
Plrg1	1.17E-03	2.30E+05	Epn1	5.28E-04	2.21E+05
Stk17b	2.13E-04	2.30E+05	Zdhhc17	3.53E-04	2.21E+05
Myct1	9.89E-04	2.30E+05	Larp4	3.70E-04	2.21E+05
Naa60	4.71E-04	2.29E+05	Rnf19b	2.45E-04	2.20E+05
Tnfsf10	1.42E-03	2.29E+05	Txndc12	9.14E-04	2.20E+05
H2afz	2.20E-04	2.29E+05	Chchd2	5.93E-04	2.20E+05
Fosb	1.35E-03	2.29E+05	Git1	1.02E-03	2.20E+05
5430405H02Rik	1.49E-03	2.29E+05	Eif3l	4.84E-04	2.20E+05
ENSMUST00000136319	2.86E-04	2.29E+05	Zfp64	4.25E-04	2.20E+05
Zfp191	1.15E-03	2.28E+05	Cox14	7.03E-04	2.19E+05
Cdc42ep3	5.29E-04	2.28E+05	Smad3	1.46E-03	2.19E+05
Fbxo4	1.22E-03	2.28E+05	Lrrc47	1.03E-03	2.19E+05
Psmg2	7.10E-04	2.28E+05	ENSMUST00000080598	1.17E-03	2.19E+05
NAP112768-1	1.20E-03	2.28E+05	ENSMUST00000116234	3.14E-04	2.19E+05
Ctbp1	3.86E-04	2.28E+05	Ddx3x	1.14E-03	2.19E+05
Mex3a	4.51E-04	2.28E+05	Ruvbl2	1.15E-03	2.19E+05
Cops6	5.60E-04	2.27E+05	Ints2	3.15E-04	2.18E+05
Cetn2	7.30E-04	2.27E+05	Cstf2t	3.58E-04	2.18E+05
Hypk	8.71E-04	2.27E+05	Pigb	1.11E-03	2.18E+05
Emilin2	7.76E-04	2.27E+05	Rbm42	1.10E-03	2.18E+05
Cdc20	1.03E-03	2.27E+05	E2f5	7.27E-04	2.18E+05
Ranbp9	1.02E-03	2.27E+05	ENSMUST00000121927	1.42E-03	2.17E+05
Mir17hg	6.38E-04	2.27E+05	Cers2	1.13E-03	2.17E+05
Rab5a	5.11E-04	2.27E+05	Ppif	5.89E-04	2.17E+05
Ddx50	1.45E-03	2.26E+05	Txnrd1	9.00E-04	2.17E+05
NAP058885-1	4.38E-04	2.26E+05	Chp1	1.18E-03	2.17E+05
Actr3	5.88E-04	2.26E+05	Eif3m	6.36E-04	2.17E+05
Zmat2	1.28E-03	2.26E+05	Dnaja2	3.99E-04	2.16E+05
Mthfs	2.50E-04	2.26E+05	G6pc3	7.73E-04	2.16E+05
Psm2	2.50E-04	2.25E+05	Glr3	1.19E-03	2.16E+05
Nap1l1	1.17E-03	2.25E+05	Syncp1	4.27E-04	2.16E+05
Mtmt12	6.99E-04	2.25E+05	Lman1	8.33E-04	2.16E+05
Xbp1	1.03E-03	2.25E+05	Ndufc1	3.86E-04	2.16E+05
Ostc	1.07E-03	2.25E+05	Isy1	9.92E-04	2.16E+05
Nono	5.61E-04	2.24E+05	Mapre1	9.45E-04	2.16E+05
Hnrnpd	1.24E-04	2.24E+05	Ppp2cb	8.22E-04	2.15E+05
Casc3	1.36E-03	2.23E+05	Pnkd	1.37E-03	2.15E+05
Dnajc16	4.44E-04	2.23E+05	Ctnnb1	1.04E-03	2.15E+05
Tbca	7.22E-04	2.23E+05	Srbd1	6.66E-04	2.15E+05
Timm17b	1.12E-03	2.23E+05	Eif3c	6.53E-04	2.15E+05
Tusc1	3.85E-04	2.23E+05	Gtf3a	1.45E-03	2.15E+05

GeneName	p-value	Fold-Change	GeneName	p-value	Fold-Change
Jak1	5.36E-04	2.15E+05	Dpy30	5.49E-04	2.08E+05
2700094K13Rik	1.01E-03	2.15E+05	S1pr4	7.65E-04	2.07E+05
Rcn1	2.36E-04	2.15E+05	Tbc1d23	1.25E-03	2.07E+05
Snw1	5.27E-04	2.14E+05	A_55_P2105017	1.01E-03	2.07E+05
Mtch1	1.09E-03	2.14E+05	Ndufa4	1.17E-03	2.07E+05
Nudt3	9.59E-04	2.14E+05	Vapb	7.86E-04	2.07E+05
Hp1bp3	1.18E-03	2.14E+05	Sdhc	1.47E-03	2.07E+05
Zfp207	9.15E-04	2.14E+05	A_55_P1952743	6.56E-04	2.07E+05
A_55_P2168781	1.52E-04	2.14E+05	Wdr12	1.18E-03	2.07E+05
Psme1	3.43E-04	2.14E+05	Prdx6	1.48E-03	2.07E+05
Gm13202	7.15E-04	2.14E+05	2410127L17Rik	1.06E-03	2.06E+05
Aldh16a1	8.40E-04	2.13E+05	NAP101548-1	1.26E-03	2.06E+05
Mapk8ip3	1.35E-03	2.13E+05	Sdr39u1	1.35E-03	2.06E+05
Rbm3	2.64E-04	2.13E+05	lpmk	6.97E-04	2.06E+05
Ifitm1	8.23E-04	2.12E+05	Ppm1h	7.98E-04	2.05E+05
A_55_P2124381	7.60E-04	2.12E+05	Aagab	1.15E-03	2.05E+05
Mavs	9.46E-04	2.12E+05	NAP114346-1	1.03E-04	2.05E+05
Sall2	9.25E-04	2.12E+05	Ndufa12	5.31E-04	2.05E+05
ENSMUST00000190438	1.25E-03	2.12E+05	Aco2	7.88E-04	2.04E+05
Sms	1.30E-03	2.12E+05	1110008F13Rik	2.21E-04	2.04E+05
Vars2	8.09E-04	2.12E+05	Ybx3	1.17E-04	2.04E+05
Glrx3	6.13E-04	2.12E+05	Psmb6	1.48E-03	2.04E+05
Gar1	2.48E-04	2.11E+05	Rnaset2a	1.35E-03	2.03E+05
Wdr36	1.35E-03	2.11E+05	Pycr2	1.14E-03	2.03E+05
A_66_P135804	1.14E-03	2.11E+05	Gm9238	3.19E-04	2.03E+05
Xylt2	9.96E-04	2.11E+05	Lman2	7.25E-04	2.03E+05
Atp5g3	5.41E-04	2.11E+05	Wbp1l	1.05E-03	2.03E+05
Eif5	1.22E-03	2.11E+05	Arl2bp	1.35E-03	2.03E+05
P3h3	1.11E-03	2.11E+05	Casp7	9.05E-04	2.03E+05
Slc25a17	7.17E-04	2.11E+05	Hacd3	9.67E-04	2.03E+05
Appbp2	5.88E-04	2.11E+05	Ppip5k2	5.52E-04	2.03E+05
Ier3ip1	6.33E-04	2.10E+05	Rpl22l1	1.42E-03	2.02E+05
Ifitm3	2.57E-04	2.10E+05	Cd34	5.93E-04	2.02E+05
Shc1	1.33E-03	2.10E+05	Wdr75	1.28E-04	2.02E+05
Cited2	9.87E-04	2.10E+05	A_55_P2045512	5.05E-04	2.02E+05
Sin3b	1.12E-03	2.10E+05	Fzr1	4.56E-04	2.02E+05
Supt3	1.19E-03	2.10E+05	Atad3a	1.08E-03	2.01E+05
Rbm8a	4.10E-04	2.10E+05	Gimap1os	1.44E-04	2.01E+05
Vdac2	1.00E-03	2.09E+05	Zfp148	2.45E-04	2.01E+05
Nif3l1	7.38E-04	2.09E+05	Sod1	1.23E-03	2.01E+05
Ehd4	3.41E-04	2.09E+05	ENSMUST00000178807	1.27E-03	2.01E+05
Prkrir	1.09E-03	2.09E+05	Tceb1	9.08E-04	2.00E+05
Ubiad1	1.30E-03	2.09E+05	Rap1b	5.16E-04	2.00E+05
Pa2g4	3.36E-04	2.09E+05	Hmgb3	5.74E-04	2.00E+05
Smtn	5.91E-04	2.09E+05	Usp7	9.83E-04	2.00E+05
Dnajc8	4.32E-04	2.09E+05	Atmin	1.07E-03	2.00E+05
Hspa4	3.61E-04	2.09E+05	Nup210	1.40E-03	2.00E+05
Vkorc1	7.56E-04	2.09E+05	Gm15421	1.24E-03	2.00E+05
Adrm1	9.01E-04	2.09E+05	Hid1	8.81E-04	1.25E+05
Cherp	1.15E-03	2.08E+05	ENSMUST00000148936	2.26E-04	1.18E+05
Metap2	5.09E-04	2.08E+05	Slc39a13	4.48E-04	1.05E+05
Gm5526	1.25E-03	2.08E+05	Mtus1	3.28E-04	8.87E+04
Clic4	1.45E-03	2.08E+05	Dlg3	2.20E-04	8.34E+04

GeneName	p-value	Fold-Change	GeneName	p-value	Fold-Change
Atp5s	1.03E-03	4.81E+04	Resp18	1.37E-04	-3.33E+05
Cep170	1.19E-04	4.80E+04	Tusc5	1.48E-03	-3.47E+05
Ndr3	3.25E-04	4.51E+04	Gjb2	1.12E-03	-3.62E+05
Cxadr	1.36E-03	4.47E+04	A_55_P1964677	1.22E-03	-4.48E+05
Mmrn1	1.02E-03	3.73E+04	A_55_P1998821	1.35E-03	-5.11E+05
Tmbim1	2.81E-04	3.72E+04			
Tle1	1.66E-04	3.69E+04			
Rpia	1.07E-03	3.63E+04			
Cebpb	6.45E-04	3.19E+04			
Gda	1.25E-04	3.19E+04			
ENSMUST00000122443	6.41E-04	3.12E+04			
Kcnk5	2.42E-04	3.05E+04			
Hlx	8.77E-04	3.00E+04			
A_55_P2075358	2.25E-04	2.82E+04			
Rufy1	1.41E-04	2.79E+04			
Ahsa1	1.05E-03	2.77E+04			
ENSMUST00000103410	1.10E-04	2.69E+04			
Pgp	1.40E-03	2.67E+04			
PPP2R5C	4.90E-04	2.67E+04			
TSPAN3	4.79E-04	2.65E+04			
Farsa	9.42E-04	2.64E+04			
Tsn	1.49E-03	2.59E+04			
Bag3	1.20E-03	2.58E+04			
Ccnd3	6.41E-04	2.57E+04			
Eif5a	4.14E-04	2.56E+04			
Dis3	1.06E-03	2.54E+04			
MAPK14	1.29E-03	2.53E+04			
Msl3	4.24E-04	2.47E+04			
Prep	2.02E-04	2.46E+04			
NAP11315-1	2.84E-04	2.44E+04			
Ebi3	8.15E-04	2.42E+04			
NAP097543-001	4.75E-04	2.30E+04			
NAP094260-001	8.99E-04	2.28E+04			
Ik	1.36E-03	2.24E+04			
Tcp1	7.68E-04	2.23E+04			
CalM3	2.27E-04	2.23E+04			
Tmem98	1.16E-03	2.22E+04			
Tmem14c	5.97E-04	2.19E+04			
UQCRC2	7.37E-04	2.17E+04			
Zfand5	9.31E-04	2.13E+04			
Morf4l2	5.90E-04	2.09E+04			
Atp5k	1.16E-03	2.09E+04			
SUPT6	7.14E-04	2.09E+04			
Ddx24	9.63E-04	2.08E+04			
Tmem147	2.28E-04	2.08E+04			
CARKD	7.26E-04	2.07E+04			
MRPL55	1.46E-03	2.04E+04			
Zfand3	7.83E-04	7.28E+03			
P2RY10	5.07E-04	3.70E+03			
RNF215	5.99E-04	2.70E+03			
ABCD3	5.97E-04	2.35E+03			
OLFR93	6.89E-04	-2.53E+05			
DDR2	5.95E-04	-3.07E+05			

Supplemental Table 6: Antibodies used for flow cytometry.

Antibody	Clone	Conjugate	Source
CD3	17A2	BV785	Biolegend
CD3e	145-2C11	PE-Cy7	Biolegend
CD11a	2D7	PE, PerCPy5.5	BD Biosciences
CD11b (Mac1)	M1/70	AF700	Biolegend
CD45.1	A20	APC-Cy7, BV421, BV510	Biolegend
CD45.2	104	AF700, FITC	Biolegend
CD45	30-F11	AF700, BV510, BV650, FITC	Biolegend
CD45R (B220)	RA3-6B2	APC, BV421, BV711	Biolegend
CD48	HM48-1	APC-Cy7	Biolegend
CD117 (c-kit)	ACK2	BV510	Biolegend
CD117 (c-kit)	ACK2	PE-Cy7, AF700	eBioscience
CD150	TC-12F12.2	BV421	Biolegend
CD182 (CXCR2)	SA044G4	FITC, PE	Biolegend
Gr1	RB6-8C5	BV510, BV786, APC-Cy7	Biolegend
Ki67	SolA15	FITC, PE-Cy7	eBioscience
Lineage Cocktail	-	APC	BD Biosciences
Ly6C	HK1.4	BV510, FITC, PerCpCy5.5	Biolegend
Ly6G	1A8	APC-Cy7, BV510	BD Biosciences
Sca-1 (Ly-6A/E)	D7	PE, PE-CF594	BD Biosciences

Supplemental Table 7: Gene expression assays used in the study.

Gene Name	Assay-ID	Source
CXCR2	Mm99999117_s1	Applied Biosystems
GAPDH	Mm99999915_g1	Applied Biosystems

Appendix

Pending or approved patents held by various authors (alphabetical).

Halvard Bonig

1. Co-inventor on patent PCT/EP2015/066083, receives royalties and licensing fees,

John DiPersio

1. "Methods and compositions for up-regulating MHC Class II" (U.S. Provisional Application No. 62/798,630)
2. "Use of IL-7 and CAR-T" (U.S. Provisional Application No. 62/712,803)
3. "Method for genome-editing and transduction of T cells" (U.S. Provisional Application No. 62/678,886)
4. "Genome-edited iNKT cells" (U.S. Provisional Application No. 62/678,883)
5. "Suppression of cytokine release syndrome" (U.S. Provisional Application No. 62/679,597)
6. "Dual and tandem CAR-T" (U.S. Provisional Application No. 62/678,878)
7. "Compositions and methods for prolonging organ transplant survival" (U.S. Provisional Application No. 62/661,295)
8. "Gene editing of CAR-T" (Application No. PCT/US2017/045304" and U.S. and foreign counterparts)

David Griggs

1. US2006240001A. P-cadherin antibodies.
2. US2003232367A. Differentially expressed genes involved in angiogenesis, the proteins encoded thereby, and methods of using the same.
3. US2004167067A. ESM-1 gene differentially expressed in angiogenesis, antagonists thereof, and methods of using the same.
4. WO04021978A. Antisense modulation of endothelial specific molecule1 expression.
5. US8716226. 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists (granted)
6. US9085606. Beta amino acid derivatives as integrin antagonists (granted)
7. WO2017117538. Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists with improved pharmacokinetic properties (pending)
8. 62/471,882. $\alpha\text{V}\beta\text{1}$ integrin antagonists (pending)

Richard Heier

1. Devadas, Balekudru; Hartmann, Susan Joyce; **Heier, Richard Frederick**; Jerome, Kevin Dewayne; Kolodziej, Stephen Anthony; Mathias, John Paul; Norton, Monica Brown; Promo, Michele Ann; Rucker, Paul Vincent; Selness, Shaun Raj. Pyridinone pyrazole urea and pyrimidinone pyrazole urea derivatives as p38 kinase inhibitors

and their preparation and use in the treatment of asthma. PCT Int. Appl. (2007), WO 2007091176 A1 20070816.

2. McCall, Robert B.; Meglasson, Martin Durham; Acker, Brad A.; **Heier, Richard Frederick**; Jin, Alan Q.; Moon, Malcolm Wilson. (5R)-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione and method of preparation thereof. U.S. Pat. Appl. Publ. (2006), US 20060040929 A1 20060223.
3. Yang, Fan; Zhang, Bo; Wicnienski, Nancy Anne; Pfefferkorn, Jeffrey Allen; Greene, Meredith L.; Chen, Ke; Nugent, Richard A.; Reding, Matthew Todd; Kelly, Robert Charles; Mitchell, Mark A.; et al. Preparation of 2-substituted {[2-(2- arylacetyl)hydrazono]methyl}benzene derivatives as inhibitors of HCV NS5b polymerase. U.S. Pat. Appl. Publ. (2005), US 20050154056 A1 20050714.
4. Clare, Michael; Fletcher, Theresa Reher; Hamper, Bruce C.; Hanson, Gunnar A.; **Heier, Richard F.**; Huang, He; Lennon, Patrick J.; Oburn, David S.; Reding, Matthew T.; Stealey, Michael A.; et al. Preparation of substituted pyrazole ureas for the treatment of inflammation. PCT Int. Appl. (2005), WO 2005037797 A1 20050428.
5. Acker, Brad A.; **Heier, Richard F.**; Jin, Alan Q.; Moon, Malcolm W. (5R)-(methylamino)-5,6-dihydro-4h-imidazo[4,5,1-ij]quinoline-2(1H)-thione. PCT Int. Appl. (2001), WO 2001083483 A1 20011108.
6. Moon, Malcolm W.; **Heier, Richard F.**; Morris, Jeanette K. Preparation of aminoheterocycloquinolines as central nervous system agents. PCT Int. Appl. (1990), WO 9015058 A1 19901213.
7. Moon, Malcolm; **Heier, Richard F.** Aminoalkynylimidazolidinones and analogs as central cholinergic agents. PCT Int. Appl. (1990), WO 9004588 A1 19900503.
8. Moon, Malcolm W.; **Heier, Richard F.** Preparation of aminoalkynylimidazoles having central nervous system activity. PCT Int. Appl. (1990), WO 9001026 A1 19900208.

Marvin Meyers

ISSUED UNITED STATES PATENTS

1. Chen, X.; Ding, K.; **Meyers, M.J.**; Tortorella, M.D.; Xu, J. Compositions and methods for the treatment of malaria. US 9,353,089. May 31, 2016.
2. Fay, L. K.; Johnson, D. S.; Kesten, S. R.; Lazerwith, S. E.; Morris, M. A.; Stiff, C. M.; **Meyers, M. J.**; Wang, J. L. Biaryl Ether Urea Compounds. US 8,044,052. October 25, 2011.
3. **Meyers, M. J.**; Arhancet, G. B.; Chen, X.; Hockerman, S. L.; Reitz, D. B.; Rico, J. G. Pyrazoline Compounds. US 7,781,428. August 24, 2010.

PUBLISHED/FILED PATENT APPLICATIONS

1. **Meyers, MJ**; Wood, DC; Arnett, SA; Yates, MP; Ruminski, PG. Fatty acid modified epidermal growth factor. *PCT application filed July 2018.*
2. **Meyers, MJ**; Singh, M; Stallings, CL; Weiss, LA; Wildman, S; Arnett, SD. Thieno[2,3-d]pyrimidines and benzofuro[3,2-d]pyrimidines as antimicrobial agents. WO 2019/018359, published January 24, 2019.
3. Dowd, D; Wang, X; Brothers, RC; John, ARO; Edwards, R; **Meyers, M**; Arnett, S; Couch, R.; Heidel, K. Novel alkenyl and beta-substituted phosphonates as antimicrobial agents. WO 2019/005982, published January 3, 2019.
4. Cao, F., Tavis, J.E., Donlin, M.J., **Meyers, M.J.**, Murelli, R.P., Orth, C., and Elgendy, B. Inhibitors of nucleotidyl

transferase superfamily enzymes as antibiotics. WO 2018/213378, published November 22, 2018.

5. Ruminski, PG; **Meyers, MJ**; Heier, RF; Rettig, MP; Dipersio, J. Integrin inhibitors in combination with an agent which interacts with a chemokine receptor. WO 2018/085578, published May 11, 2018.
6. Donlin, M.J., Tavis, J.E., Murelli, R., and **Meyers, M.J.** Anti-fungal compounds. WO 2017/184752, published October 26, 2017.
7. Tavis, J.E.; Morrison, L.A.; **Meyers, M.J.** Inhibitors of nucleotidyl transferases and use in herpes and hepatitis viral infections. WO2016/201306, published December 15, 2016.
8. Tavis, J.E.; Morrison, L.A.; **Meyers, M.J.** Inhibitors of HSV nucleotidyl transferases and uses. WO2015/077774, published May 28, 2015.
9. Blinn, J.R.; Flick, A.C.; Wennerstaal, G.M.; Jones, P.; Kaila, N.; Kiefer, Jr., J.R.; Kurumbail, R.G.; Mente, S.R.; **Meyers, M.J.**; Schnute, M.E.; Thorarensen, A.; Xing, L.; Zamaratski, E.; Zapf, C.W. Preparation of N-heteroaryl amides as RORC2 inhibitors. WO2015/015378, published Feb 5, 2015.
10. Chen, X.; Ding, K.; Meyers, M.J.; Tortorella, M.D.; Xu, J. Compositions and methods for the treatment of malaria. WO2014/160775, published Oct 2, 2014.
11. Arhancet, G. B.; Casimiro-Garcia, A.; Chen, X.; Hepworth, D.; **Meyers, M. J.**; Piotrowski, D. W.; Raheja, R. K. 4,5-Dihydro-1H-Pyrazole Compounds and Their Pharmaceutical Uses. WO2010/116282, published October, 14, 2010.
12. Long, S. A.; Wang, J. L.; **Meyers, M. J.**; Pelc, M.; Schweitzer, B. A.; Thorarensen, A. 1-Oxa-8-azaspiro[4,5]decane-8-carboxamide Compounds as FAAH Inhibitors. WO2010/058318, published May 27, 2010.
13. **Meyers, M. J.**; Schweitzer, B. A.; Pelc, M.; Wang, J. L.; Long, S. A.; Thorarensen, A. 7-Azaspiro[3.5]nonane-7-carboxamide Compounds as Modulators of Fatty Acid Amide Hydrolase. WO2010/049841, published May 6, 2010.
14. **Meyers, M. J.**; Pelc, M.; Schweitzer, B. A.; Thorarensen, A. 4-Benzylidene-3-Methylpiperidine Aryl Carboxamide Compounds Useful as FAAH Inhibitors. WO2009/127946, published October 22, 2009.
15. **Meyers, M. J.**; Pelc, M.; Thorarensen, A. 4-[3-(Aryloxy)Benzylidene]-3-Methylpiperidine Aryl Carboxamide Compounds Useful as FAAH Inhibitors. WO2009/127949, published October 22, 2009.
16. **Meyers, M. J.**; Pelc, M.; Thorarensen, A. ; Schweitzer, B. A. 4-[3-(Aryloxy)Benzylidene]-3-Methylpiperidine 5-Membered Aryl Carboxamide Compounds Useful as FAAH Inhibitors. WO2009/127948, published October 22, 2009.
17. Fay, L.; Johnson, D. S.; **Meyers, M. J.**; Thorarensen, A.; Wang, J. L. Ether Benzylidene Piperidine Aryl Carboxamide Compounds Useful as FAAH Inhibitors. WO2009/127944, published October 22, 2009.
18. Fay, L.; Johnson, D. S.; **Meyers, M. J.**; Schweitzer, B. A.; Thorarensen, A.; Wang, J. L.; Ether Benzylidene Piperidine 5-Membered Aryl Carboxamide Compounds Useful as FAAH Inhibitors. WO2009/127943, published October 22, 2009.
19. Fay, L. K.; Johnson, D. S.; Lazerwith, S. E.; Morris, M. A.; Wang, J. L.; **Meyers, M. J.**; Kesten, S. R.; Stiff, C. M. Biaryl Ether Urea Compounds. WO2008/047229, published April 24, 2008.
20. **Meyers, M. J.**; Arhancet, G. B.; Chen, X.; Hockerman, S. L.; Long, S. A.; Mahoney, M. W.; Reitz, D. B.; Rico, J.

G. Pyrazoline Compounds as Mineralocorticoid Receptor Antagonists. WO2008/053300, published May 8, 2008.

21. Anderson, D. A.; **Meyers, M. J.**, et al. Benzothiophene compounds and analogues thereof. U.S. Provisional Patent Applications PC 33367 and PC33647, filed August 20, 2007.
22. **Meyers, M. J.**; Anderson, D. R.; Hegde, S. G.; Trujillo, J. I.; Reitz, D. B.; Mahoney, M. W.; Vernier, W. F.; Buchler, I. P.; Wu, K. K. Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors. Patent Application US 2005/0101623.
23. Anderson, D. R.; Buchler, I. P.; Hegde, S. G.; Mahoney, M. W.; **Meyers, M. J.**; Reitz, D. B.; Trujillo, J. I.; Vernier, W. F.; Wu, K. K. Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors. Patent Application US 2005/0137220.
24. **Meyers, M. J.**; Reitz, D. B.; Anderson, D. R.; Hegde, S. G.; Mahoney, M. W. Beta-carboline compounds and analogues thereof as mitogen-activated protein kinase-activated protein kinase-2 inhibitors. Patent Application US 2005/0143371.
25. Vernier, W. F.; Anderson, D. R.; Phillion, D. P.; **Meyers, M. J.**; Hegde, S. G.; Reitz, D. B.; Buchler, I. P.; Mahoney, M. W.; Rogers, T. E.; Poda, G.; Singh, M.; Wu, K. K.; Xie, J. Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds. Patent Application US 2004/0209897.
26. Hanau, C. E.; Mershon, S. M.; Graneto, M. J.; **Meyers, M. J.**; Hegde, S. G.; Buchler, I. P.; Wu, K. K.; Liu, S.; Nacro, K. Acyclic pyrazole compounds for the inhibition of mitogen activated protein kinase-activated protein kinase-2. Patent Application US 2004/0152739.

Michael Rettig

1. "Methods and compositions for up-regulating MHC Class II" (U.S. Provisional Application No. 62/798,630)

Peter Ruminski

1. **VLA4 Integrin Antagonists.** *Provisional US Patent Application USTL.P0080US.P1 (2017)*
2. **$\alpha_v\beta_1$ INTEGRIN ANTAGONISTS.** *Provisional US Patent Application USTL.P0082US.P1 (2016)*
3. **Preparation of 3,5-phenyl substituted beta amino acid derivatives as integrin receptor antagonists.** *U.S. Pat. Appl. Publ. (2014), US 20140051715 A1 20140220*
4. **Beta Amino Acid Derivatives as Integrin Antagonists.** *US patent 9085606*
5. **3,5-phenyl substituted beta amino acid derivatives as integrin antagonists.** *US patent 8716226*
6. **Preparation of N-glycyl-beta amino acid derivatives as integrin antagonists.** *WO 2014015054 A1*
7. **Preparation of pyrimidine and pyridine derivatives as antiinflammatory agents.** *WO Patent 2009016498*
8. **Hetero bicyclic carboxamide derivatives, processes for preparing them, pharmaceutical compositions containing them, and their uses as inhibitors of matrix metalloproteinase enzymes.** *WO Patent 2008149191*
9. **Preparation of beta -amino acid R-isomer compounds as integrin receptor antagonists.** *WO Patent 2004060376*

10. Preparation of peptidyl integrin antagonists for use in combination with a chemotherapeutic agent for treatment of neoplasia. *US Patent 6372719*
11. Preparation of peptidyl integrin antagonists for use in combination with a chemotherapeutic agent for treatment of neoplasia. *WO Patent 2000051686*
12. Preparation of [(((pyrimidinylamino)benzoyl)amino]acetyl]amino]benzenepropanoic acid derivatives as avb3 integrin antagonists. *US Patent 6013651*
13. Preparation of heterocyclic glycol beta -alanine derivatives as vitronectin antagonists. *WO Patent 9952896*
14. Preparation of 3-hydroxy-5-[(1,4,5,6-tetrahydro-5-hydroxy-2-pyrimidinyl)amino]benzoic acid. *WO Patent 9944996*
15. Preparation of meta-pyrimidinylamino benzamides and derivatives as avb3 integrin antagonists. *WO Patent 9944994*
16. Preparation of cinnamic acid derivatives for selective inhibiting or antagonizing the avb3 integrin. *US Patent 5852210*
17. Preparation of 3-guanidinophenylamides and related compounds as integrin avb3 inhibitors or antagonists. *US Patent 5773646*
18. Platelet aggregation inhibitors *US Patent 5798370*
19. New vitronectin receptor antagonizing amino-benzoic acid derivatives used to treat e.g. tumor metastasis, solid tumor growth, angiogenesis, osteoporosis, smooth muscle migration and rheumatoid arthritis. *WO Patent 9708145*
20. Guanidinoalkyl glycine beta-amino acids useful for inhibiting tumor metastasis. *US Patent 5681820*
21. Guanidinoalkyl glycine beta-amino acids useful for inhibiting bone loss. *US Patent 563976*
22. Benzamido phenyl or phenoxy acetic and propionic acids for use in arthritis, tumor growth and metastasis, osteoporosis, etc. *WO Patent 973686*
23. New guanidino phenyl styryl alkenoic acids for use in arthritis, tumor growth and metastasis, osteoporosis, restenosis, etc. *WO Patent 9736860*
24. Benzamido phenyl propionic and phenoxyacetic acids for use in arthritis, tumor growth and metastasis, osteoporosis, restenosis, etc. *WO Patent 9736859*
25. Platelet aggregation inhibitors. *US Patent 5602155*
26. Guanidino alkylamino carbonyl alkyl carbamido alkanolic acid derivatives are platelet aggregation inhibitors used in thrombosis, stroke, infarction, arteriosclerosis, inflammation, metastasis, etc. *WO Patent 9623771*
27. Fluoroalkenyl compounds and their use as pest control agents. *US Patent 5811578*
28. Fluoroalkenyl compounds and their use as pest control agents. *US Patent 5723470*
29. Fluoroalkenyl compounds and their use as pest repellents. *US Patent 571451*

30. **Fluoroalkenyl compounds and their use as pest control agents.** *US Patent 5708032*
31. **New 4,4-difluoro-but-3-enyl esters of carboxylic acid, useful as pesticides in plant protection.** *WO Patent 9708130*
32. **New N,N-disubstituted 4-bromo-3-chloro-3,4,4-trifluoro-butanamide- used to control nematodes, insects and acarids in agricultural crops, and glycine derivative, intermediate for trifluorobutene compounds.** *US Patent 5700840*
33. **Fluoroalkenyl compounds and their use as pest control agents.** *US Patent 562717:*
34. **Fluoroalkenyl compounds and their use as pest repellents.** *US Patent 569386*
35. **Fluoroalkenyl compounds and their use as pest repellents.** *US Patent 562308*
36. **New 3,4,4-trifluorobutenoic acid derivatives useful for controlling nematode, insect and acarid infestation of plants.** *US Patent 551471*
37. **New fluoro substituted alkenyl ether and thioether compounds useful as pesticides in plant protection.** *WO Patent 9619449*
38. **New fluoro substituted butenyl ester compounds useful as pesticides in plant and material protection and veterinary medicine.** *WO Patent 9614289*
39. **New fluoro butenyl carbonate and carbamate compounds useful as pesticides in plant protection.** *DE Patent 443933*
40. **Preparation of difluorobutenyloxy acetate and difluorobutenyl thioacetate derivatives as pesticides.** *DE Patent 4445792*
41. **Fluoroalkenyl compounds and their use as pest repellents.** *US Patent 5561162*
42. **Fluoroalkenyl compounds and their use as pest repellents.** *US Patent 5457134*
43. **Fluoroalkenyl compounds and their use as pest repellents.** *US Patent 5389680*
44. **Fluoroalkenyl compounds for nematode, insect and acarid control.** *WO Patent 921555*
45. **Preparation of fluoroalkenyl group containing compounds as pesticides.** *CN Patent 1064479*
46. **2,6-bis(trifluoromethyl)-3-hydroxy carbonyl pyridines as gametocides.** *US Patent 4747871*
47. **2,6-bis (trifluoromethyl)-3-methoxycarbonyl-4-hydroxy pyridines as gametocides.** *EP Patent 276204*